Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $22.95 | Total: $114.75 |
| 1 | 10 | $19.44 | Total: $194.40 |
| 1 | 25 | $16.47 | Total: $411.75 |
| 1 | 50 | $14.04 | Total: $702.00 |
| 1 | 100 | $12.15 | Total: $1,215.00 |
Overview
CAN508 is a potent ATP-competitive CDK9cyclin T1 inhibitor with an IC50 of 0.35 ?M. It also competitively inhibits Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 ?M and 20 ?M, respectively. CAN508 exhibits a 38-fold selectivity for CDK9cyclin T over other CDKcyclin complexes. [Antitumor activity.]
Chemical Properties
| Molecular Formula | C9H10N6O |
| Molecular Weight | 218.22 |
| CAS Numbers | 140651-18-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Nc1n[nH]c(N)c1N=Nc1ccc(O)cc1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49[22] 6500-6509.